Business
This week, a focus on key results from the American Society of Hematology meeting: Jaypirca headed for the front line; Kite’s Anito-cel in multiple myeloma; next-generation CAR-T approaches; Kelownia’s early in vivo CAR-T data; and Novartis’s ianalumab’s potential in ITP.
The US FDA approved Uplizna (inebilizumab) for generalized myasthenia gravis, an increasingly crowded market. Amgen believes it can compete due to the CD19-targeting antibody’s durable efficacy with twice-yearly dosing.
Arcus is ending development of its TIGIT-targeted antibody domvanalimab after it was determined a Phase III study would not show a survival benefit in gastrointestinal cancers.
The Switzerland-based group’s alpha-synuclein-targeted immunotherapy shows promise in slowing progression of the degenerative brain condition.
Merck & Co.’s checkpoint inhibitor Keytruda remains the best-selling drug worldwide. The top 10 products generated nearly $47bn in third-quarter revenues for big pharma, boosted by swelling sales of obesity drugs.
Having worked in stealth on its predictive computational R&D models, PsiThera has emerged to develop oral versions of blockbuster drug targets in inflammation and immunology.
Now in their 21st year, the Scrip Awards celebrated biopharma successes at the 2025 ceremony in London’s Mayfair, where AstraZeneca and Noubar Afeyan took home the top prizes.
Triple agonist retatrutide yielded 28.7% weight loss at 68 weeks, besting Zepbound’s Phase III data, while also showing benefit in knee osteoarthritis pain.
Subsidiary Pulmovant plans to report Phase II data in pulmonary hypertension associated with interstitial lung disease in 2026, one of several programs highlighted during an investor event.
The deal, which could be worth as much as $1.7bn, looks to use Relation's AI capabilities to power the discovery of potentially first-in-class immuno-dermatology targets.
FOPO Edition: Capitalizing on positive data, eight drug developers priced follow-on public offerings that brought in $3.2bn, including $650m each for Terns and Structure plus $602m for Kymera.
GSK builds up its arsenal of antibody-drug conjugates, while Oxford BioTherapeutics adds another pharma heavyweight to its expansive roster of partners.
With its M&A war chest diminished and still seeking to add to its weight-management pipeline, Pfizer obtains an oral GLP-1 analog from Fosun subsidiary YaoPharma.
Early atopic dermatitis data on the oral STAT6 degrader helps the US firm’s hopes of matching the Sanofi and Regeneron injectable blockbuster on efficacy.
An investment only becomes appealing when all the ducks are in a row; if just one duck strays, investors can sense trouble and may hesitate before proceeding.
Dyne’s data from a larger Phase I/II trial cohort showed much greater dystrophin production with z-rostudirsen (DYNE-251) than seen with Sarepta’s Exondys 51 and some functional gains.
With three approved drugs and volixibat in pivotal studies for two cholestatic liver diseases, Mirum is betting $570m in cash and equity to pick up Bluejay’s Phase III hepatitis D candidate.
The oral GLP-1 showed efficacy on par with Lilly’s orforglipron, positioning it as a contender in the red-hot obesity drug market.
The Polish biotech says that data presented at the Orlando meeting also strengthens its confidence in the CDK8/19 inhibitor's potential across hematologic cancers with limited treatment options.
The consolidation of Biocon-BBL is expected to unlock value, deliver operational synergies and provides BBL’s minority shareholders an 'earlier liquidity event'. Investor Viatris also signals accelerated expiration of biosimilars non-compete restrictions.